STAT+: Wegovy cut patients’ chances of dying from Covid-19, new analysis showsSTAT+: Wegovy cut patients’ chances of dying from Covid-19, new analysis shows
LONDON — Novo Nordisk made worldwide headlines last year when a study demonstrated that Wegovy, its powerful and exceedingly popular weight loss medicine, helped reduce the risk of cardiovascular emergencies like heart attacks. Researchers on Friday unveiled results demonstrating another benefit that the drug offered to patients in that study: Compared to placebo, it cut Read More
STAT+: New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failureSTAT+: New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failure
Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a new analysis that could boost the company’s efforts to expand the label for the blockbuster treatment. Researchers combined data on nearly 4,000 patients across four trials who had heart failure with reduced Read More
Benefits of Neoadjuvant Immunotherapy in Breast Cancer Extend Beyond TNBCBenefits of Neoadjuvant Immunotherapy in Breast Cancer Extend Beyond TNBC
(MedPage Today) — Neoadjuvant, but not adjuvant, chemoimmunotherapy significantly improved key outcomes in certain patients with early breast cancer, according to a meta-analysis involving more than 5,000 patients.
Consistent with existing evidence…
Jim Wilson’s next venture, a surprise startup shutdown, & Lilly’s Zepbound strategyJim Wilson’s next venture, a surprise startup shutdown, & Lilly’s Zepbound strategy
What’s behind the “great abandonment” in gene therapy R&D? How does a startup spend $213 million? And is Adam an optimist? We talk about all that and more on this week’s episode of “The Readout LOUD.” STAT biotech reporter Jonathan Wosen joins us to discuss gene therapy pioneer Jim Wilson’s exit from his decades-long tenure Read More
STAT+: Pharmalittle: We’re reading about Zepbound pricing caveats, PBM congressional testimony, and moreSTAT+: Pharmalittle: We’re reading about Zepbound pricing caveats, PBM congressional testimony, and more
Rise and shine, everyone, another busy day is on the way. We can tell because the official mascots are barking at an unusually high number of doggies walking alongside the Pharmalot campus this morning and the number of motor cars driving by. And we are trying to keep pace. To do so, yes, we are Read More
Is the GLP-1 party running down for Hims, and a study for the weekendIs the GLP-1 party running down for Hims, and a study for the weekend
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in your inbox. Good morning and happy Thursday! Yesterday it was announced that my colleague Usha Lee McFarling won the 2024 Victor Cohn Prize for Excellence in Medical Science Reporting. I’m genuinely so honored to work in the same newsroom as Read More
Surgeon Care Team Network Measures and Timely Breast Cancer TreatmentSurgeon Care Team Network Measures and Timely Breast Cancer Treatment
This cross-sectional study assesses associations of surgeon and care team patient-sharing networks with access to timely treatment among patients with breast cancer.
Persistent Neighborhood Poverty and Breast Cancer OutcomesPersistent Neighborhood Poverty and Breast Cancer Outcomes
This cohort study examines tumor characteristics, treatment, and mortality in women with breast cancer living in persistently impoverished census tracts.
miR-10b inhibition: A strategy for treating metastatic breast cancermiR-10b inhibition: A strategy for treating metastatic breast cancer
A new research paper was published in Oncotarget, titled “Inhibition of miR-10b treats metastatic breast cancer by targeting stem cell-like properties.”
GLP-1 Agonists May Offer Protection Against Glaucoma in Type 2 DiabetesGLP-1 Agonists May Offer Protection Against Glaucoma in Type 2 Diabetes
(MedPage Today) — Diabetic patients treated with GLP-1 receptor agonists (GLP-1RAs) had a significantly lower risk of developing glaucoma as compared with metformin, a large retrospective cohort study showed. Patients treated with a GLP-1RA agonist… (MedPage Today) — Diabetic patients treated with GLP-1 receptor agonists (GLP-1RAs) had a significantly lower risk of developing glaucoma Read More